CN111560053A - CD133 antagonistic polypeptide, derivative and application thereof - Google Patents
CD133 antagonistic polypeptide, derivative and application thereof Download PDFInfo
- Publication number
- CN111560053A CN111560053A CN202010553810.5A CN202010553810A CN111560053A CN 111560053 A CN111560053 A CN 111560053A CN 202010553810 A CN202010553810 A CN 202010553810A CN 111560053 A CN111560053 A CN 111560053A
- Authority
- CN
- China
- Prior art keywords
- antagonist polypeptide
- polypeptide
- derivative
- cells
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040120 Prominin-1 Human genes 0.000 title claims abstract description 102
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 87
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 79
- 230000003042 antagnostic effect Effects 0.000 title claims abstract description 9
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 54
- 239000005557 antagonist Substances 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 24
- 230000006907 apoptotic process Effects 0.000 claims abstract description 12
- 230000035755 proliferation Effects 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 125000000539 amino acid group Chemical group 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 4
- -1 adsorption carrier Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 238000005576 amination reaction Methods 0.000 claims description 2
- 238000007413 biotinylation Methods 0.000 claims description 2
- 230000006287 biotinylation Effects 0.000 claims description 2
- 230000006315 carbonylation Effects 0.000 claims description 2
- 238000005810 carbonylation reaction Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000021523 carboxylation Effects 0.000 claims description 2
- 238000006473 carboxylation reaction Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 230000033444 hydroxylation Effects 0.000 claims description 2
- 238000005805 hydroxylation reaction Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000002331 protein detection Methods 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 48
- 229940079593 drug Drugs 0.000 abstract description 11
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000003321 amplification Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012917 library technology Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- GHYJGDCPHMSFEJ-GUBZILKMSA-N Gln-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GHYJGDCPHMSFEJ-GUBZILKMSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- DGYNAJNQMBFYIF-SZMVWBNQSA-N His-Glu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 DGYNAJNQMBFYIF-SZMVWBNQSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000042782 prominin family Human genes 0.000 description 1
- 108091082104 prominin family Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a CD133 antagonist polypeptide, a derivative and an application thereof, and particularly discloses a CD133 antagonist polypeptide: the amino acid residue sequence of the CD133 antagonistic polypeptide HL12-CP1 is shown as SEQ ID No.1, and the amino acid residue sequence of Gln-Gln-Met-His-Glu-Trp-Tyr-Phe-Gln-Ser-Leu-Pro is shown as SEQ ID No: 1. the binding peptide and the derivatives thereof can bind to CD133, block a downstream signal path thereof through the binding with the CD133 so as to inhibit the proliferation of colorectal cancer cells, promote the apoptosis of the colorectal cancer cells, provide effective small molecule treatment medicines for colorectal cancer and the like, and can be widely applied in the fields of medicine and biology.
Description
Technical Field
The invention relates to the field of biotechnology and biomedicine, in particular to a colorectal cancer target CD133 receptor antagonist polypeptide HL12-CP1 and derivatives and application thereof.
Background
1.1 colorectal cancer
Colorectal cancer (CRC) is one of the most common malignancies in the world. The International Agency for Research on Cancer (IARC) report of the world health organization indicates that the incidence of colorectal Cancer is located at the 3 rd position of malignant tumor after lung Cancer and breast Cancer, and the mortality is located at the 4 th position of malignant tumor after lung Cancer, liver Cancer and stomach Cancer. Colorectal cancer incidence region distribution has obvious difference in the world, and the incidence rate in European and American regions is higher than that in Asian regions. The CRC incidence rate of China is 29/10 ten thousand, and the death rate is 14/10 ten thousand. However, with the continuous improvement of the living standard of the substance, the change of the living style, especially the change of the eating habit, the incidence rate of colorectal cancer in China shows a trend of gradually rising. In contrast, the incidence and fatality rate of colorectal cancer has been significantly reduced in the european and american countries over the last 20 years due to the early development of colorectal cancer screening. Compared with European and American countries, the colorectal cancer of Chinese presents the characteristics of three highs and one lowness: 1. the incidence rate of colon cancer is slightly lower than that of rectal cancer, but the incidence rate of colon cancer is in an increasing trend in recent years; 2. the low rectal cancer accounts for a higher proportion; 3. the proportion of young people is about 10-15%; 4. the early screening and diagnosis rate is low.
At present, the cause of colorectal cancer is not completely clear, but with the continuous development and research of medicine and molecular biology, the development and development of colorectal cancer are gradually realized as the evolution process of 'inflammation-hyperplasia-canceration' caused by the joint action of multiple genes and the participation of multiple signal pathways. Domestic and foreign researches find that gene mutation of K-ras, methylation of DNA molecules and insulin-like growth factors are important reasons for promoting CRC generation and development. With the continuous research on CRC etiology, high-risk factors related to the CRC pathogenesis are gradually recognized, such as long-term high fat intake, nitrite compound food intake, vitamin deficiency, long-term alcoholism and other dietary factors; ulcerative colitis, colon adenoma, Familial Adenomatous Polyposis (FAP), and the like are diseases considered as precancerous lesions; factors such as age increase (> 60 years) and family inheritance are high risk factors for CRC.
At present, the treatment means of the colorectal cancer patient mainly comprises surgical treatment, chemical drug treatment and radioactive ray radiation treatment. Among them, surgery is currently the most important and effective means for colorectal cancer treatment, and radiotherapy and chemotherapy have become important components of adjuvant therapy for colorectal cancer. Meanwhile, therapeutic means such as targeted therapy, gene therapy, neoadjuvant chemotherapy, immunotherapy, etc. are also increasingly applied. Molecular targeted drug therapy has significant efficacy in specific patients, and patients benefit from survival. However, the application of targeted drugs is limited mainly because the effective targets of the existing targeted drugs are few, and the corresponding molecular target detection needs to be carried out on patients before the appropriate targeted therapeutic drugs are selected. Currently, for CRC patients, the main two targeted drugs are bevacizumab targeting Vascular Endothelial Growth Factor (VEGF) and cetuximab targeting Epidermal Growth Factor Receptor (EGFR). The study of domestic scholars suggests that patients with advanced and late colorectal cancer benefit from using cetuximab and bevacizumab for survival.
1.2 CD133 and colorectal cancer Stem cells
Tumor stem cells (CSCs) are a group of cells that are self-renewing and immortalized in tumor tissue and that have functions similar to normal tissue stem cells and promote the maintenance of tumor growth, and have a multi-differentiation potential and can differentiate to generate different tissue cells. The source of the compound is not yet determined, and at present, two main points are provided; one view is that tumor stem cells are derived from the original normal stem cell mutation in the body; another view is that tumor stem cells are formed by mutating the gene of progenitor cells. In addition, some researchers have suggested that tumor stem cells may be the result of bone marrow-derived stem cell mutations. Research has now isolated tumor stem cells from tumor tissues that have developed ovarian, pancreatic, brain, and rectal cancers. CD133, also known as Prominin-1, is a glycoprotein with 5 transmembrane domains and 2 extracellular domains, a member of the Prominin family, and was originally used as a marker for hematopoietic stem/progenitor cells. In 2006O, Brien et al isolated CD133+ tumor cells from colorectal cancer specimens for the first time and found that CD133+ had a tumorigenic capacity, suggesting that CD133 might be colorectal cancer tumor stem cells. Subsequent studies by Cherciu et al suggested that CD44, CD133, 0et4, ALDHl, CDl66, CD24, etc. might be stem cell markers for colorectal cancer tumor markers. With the increasing reports of research on colorectal cancer tumor stem cell markers, CD44/CD133 is a commonly used marker of colorectal cancer tumor stem cells at present, and high expression of CD44/CD133 is a risk factor influencing the prognosis of patients.
1.4 phage display technology
Phage Display Technologies (PDT) was proposed by Smith et al in 1985; in 1988, the phage display peptide library was successfully constructed for the first time; from 1990 to date, phage display peptide libraries have been rapidly developed and applied. The principle of the phage display technology is that external DNA is cloned to a proper phage vector through a genetic engineering technology, so that an expression product corresponding to an exogenous DNA fragment is fused on capsid protein of the phage to form fusion protein, the fusion protein is displayed on the surface of the phage, and displayed polypeptide or protein can keep relative spatial structure and biological activity. Then washing off the phage which is not specifically combined by using the target molecule and adopting a proper elutriation method, and finally screening out the target phage which can be combined with the target molecule from the phage library; the foreign polypeptide or protein is expressed on the surface of the phage, and its encoding gene can be sequenced as part of the phage genome by phage DNA sequence. The technology has the obvious characteristic of establishing the corresponding relation between the genotype and the phenotype. The phage display technology is suitable for preparing fully human antibody medicaments. Humira, an anti-TNF alpha, for the treatment of rheumatoid arthritis was the first fully human antibody drug produced using phage antibody library technology and approved by the U.S. food and drug administration. By 2014, 6 antibodies produced using phage antibody library technology approved by the U.S. food and drug administration, and 30 or more related drugs at the same time are in clinical trial. In addition to screening for production antibodies, phage antibody library technology can also be used to screen for the corresponding antigen. Therefore, the antibody library of the phage display technology is widely applied in many fields of life science due to the advantages of high storage capacity, high efficiency, convenience, flexible screening and the like, and particularly receives more and more attention in the fields of tumor diagnosis, tumor antibody drug preparation and the like, and can be used as a favorable tool for screening the non-small cell lung cancer surface antigen targeted antibody.
Disclosure of Invention
In order to overcome the defects and shortcomings of the prior art, the primary object of the present invention is to provide a CD133 antagonist polypeptide, which has high specific affinity with the receptor CD133 and can block the signal pathway of CD133 by binding with CD133, thus proving that the polypeptide plays an important role in targeted inhibition of proliferation of colorectal cancer cells, promotion of apoptosis of colorectal cancer cells, etc., and has great application value in targeted therapy of colorectal cancer.
It is another object of the present invention to provide derivatives of the aforementioned antagonist polypeptides for CD133 receptor, which derivatives also have specific high affinity for CD133 receptor and specifically bind to CD 133.
It is still another object of the present invention to provide the use of the above-mentioned CD133 antagonist polypeptide and its derivatives.
In order to realize the task, the invention adopts the following technical solution:
one aspect of the present invention provides a CD133 antagonist polypeptide, the amino acid sequence of which is shown in SEQ ID No.1,
Gln-Gln-Met-His-Glu-Trp-Tyr-Phe-Gln-Ser-Leu-Pro SEQ ID No：1。
the screening method of the CD133 antagonistic polypeptide utilizes a phage random peptide library, firstly CD133 plasmid is used for transfecting 293T cells to obtain a stable cell line permanently expressing CD133 at a high level, wild type 293T cells are used as control adsorption cells, 5 rounds of whole cell subtractive screening are carried out, 50 positive phage are randomly picked for amplification, and a clone single-stranded DNA is extracted for sequencing. The basic characteristics of the amino acid sequence of the polypeptide are analyzed, polypeptide homology comparison is carried out, and a polypeptide motif with high occurrence frequency is searched.
In another aspect, the present invention provides a derivative of a CD133 antagonist polypeptide, wherein the derivative of the CD133 antagonist polypeptide is a product obtained by conventionally modifying an amino acid side chain group of the CD133 antagonist polypeptide, an amino terminus or a carboxyl terminus of a segment of the CD133 antagonist polypeptide, or a product obtained by attaching a tag for polypeptide or protein detection or purification to the CD133 antagonist polypeptide; the conventional modification is preferably amination, amidation, hydroxylation, carboxylation, carbonylation, alkylation, acetylation, phosphorylation, esterification, glycosylation, cyclization, biotinylation, fluorescent group modification, polyethylene glycol (PEG) modification or immobilization modification and the like; the tag is preferably His6GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc, or ProfinityXact, etc.
The derivative of the CD133 antagonist polypeptide is preferably: the CD133 antagonist polypeptide is amidated at the terminal.
The hydrophilicity analysis shows that the CD133 antagonist polypeptide HL12-CP1 is a hydrophilic polypeptide;
the CD133 antagonist polypeptide and derivatives thereof can be derived from mammals or birds, such as primates (humans); rodents, including mice, rats, hamsters, rabbits, horses, cattle, canines, cats, and the like.
The CD133 antagonistic polypeptide and the derivative thereof are obtained by adopting a known method in the prior art, and can be chemically synthesized by using an automatic polypeptide synthesizer; deducing a nucleotide sequence from the short peptide sequence, and cloning the nucleotide sequence into a vector for biosynthesis; it can also be extracted and purified in large quantities from existing organisms.
In a further aspect, the present invention provides a polynucleotide encoding the polypeptide of SEQ ID No. 1.
In a further aspect of the invention, there is provided a vector comprising a nucleotide according to the invention, which can be linked to a promoter sequence by gene technology means.
In a further aspect, the invention provides a host cell transfected with a vector according to the invention.
In a further aspect, the invention provides a medicament comprising a CD133 antagonist polypeptide or a derivative thereof.
In the technical scheme of the invention, the medicine contains one or more pharmaceutically acceptable carriers;
in the technical scheme of the invention, the pharmaceutically acceptable carrier is preferably diluent, excipient, filler, adhesive, wetting agent, disintegrant, absorption enhancer, adsorption carrier, surfactant or lubricant;
in the technical scheme of the invention, the medicine can be further prepared into various forms such as tablets, granules, capsules, oral liquid or injections, and the medicines of various formulations can be prepared according to the conventional method in the pharmaceutical field.
In yet another aspect, the invention provides a detection reagent comprising a CD133 antagonist polypeptide or a derivative thereof.
In a further aspect, the invention provides antibodies to the aforementioned CD133 antagonist polypeptide or derivatives of the CD133 antagonist polypeptide.
In another aspect, the invention provides the use of the CD133 antagonist polypeptide and the derivative of the CD133 antagonist polypeptide in the preparation of a medicament for inhibiting the proliferation of tumor cells highly expressing CD 133.
In another aspect, the invention provides the use of the CD133 antagonist polypeptide and derivatives of the CD133 antagonist polypeptide in the preparation of a medicament for promoting apoptosis of tumor cells highly expressing CD 133.
In the technical scheme of the invention, the tumor cells highly expressing CD133 are selected from rectal cancer cells, colon cancer cells, bile duct cancer cells, glioma cells, endometrial cancer cells, lung cancer cells and gastric adenocarcinoma cells.
In another aspect, the invention provides the use of the CD133 antagonist polypeptide, or a derivative of the CD133 antagonist polypeptide, in the preparation of a medicament for treating a tumor disease with high CD133 expression.
In the technical scheme of the invention, the tumor diseases with high expression of CD133 are selected from rectal cancer, colon cancer, bile duct cancer, glioma, endometrial cancer, lung cancer and gastric adenocarcinoma.
In the specific experiment of the invention, the CD133 antagonist polypeptide HL12-CP1 can be used for specificity and high expression of CD133 in 293T CD133 cells+/+And (4) combining.
In further experiments, the function of the CD133 antagonist polypeptide HL12-CP1 is verified by using the colorectal cancer cell HCT-116 with high expression of CD133 as a cell model, and HL12-CP1 can obviously inhibit the proliferation of the colorectal cancer cell HCT-116 compared with a control group.
In another specific experiment of the invention, the CD133 antagonist polypeptide HL12-CP1 is detected to promote the apoptosis of HCT-116 by adopting a flow cytometry technology.
Advantageous effects
(1) The invention provides a CD133 antagonist polypeptide HL12-CP1 and derivatives thereof, wherein the antagonist polypeptide and the derivatives thereof can be specifically combined with CD133 and specifically combined with the CD133 to inhibit a CD133 signal channel.
(2) The CD133 antagonistic polypeptide and the derivative thereof obtained by screening can inhibit the proliferation of colorectal cancer cells by blocking a signal channel of CD133 and promote the apoptosis of the colorectal cancer cells, can be used as a biological polypeptide drug of a CD133 binding site, and can be used for preparing a drug for preventing and/or treating colorectal cancer. Can be widely applied in the medical and biological fields and can generate huge social and economic benefits.
Drawings
FIG. 1: CD133 and HL12-CP1 polypeptide hydrophobic profile comparison analysis. Wherein: a: CD133 hydrophobic profile; b: HL12-CP1 polypeptide hydrophobic profile map; c: CD133 and HL12-CP1 polypeptide hydrophobic profile comparison chart. The CD133 profile is red and the HL12-CP1 profile is blue (indicated with arrows);
FIG. 2: the ability of HL12-CP1 phage to bind to CD 133;
FIG. 3: HL12-CP1 inhibits the proliferation of HCT-116 cells of colorectal cancer;
FIG. 4: HL12-CP1 promoted apoptosis of HCT-116. A: detecting apoptosis of cells in a control group by using a flow cytometer; b: detecting apoptosis of HL12-CP1 administration group by a flow cytometer; c: and (5) counting apoptosis data.
Detailed Description
In order that the invention may be more clearly understood, it will now be further described with reference to the following examples and the accompanying drawings. The examples are for illustration only and do not limit the invention in any way. In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.
Example 1: and (3) carrying out panning, amplification, purification, sequencing and synthesis on the CD133 antagonist polypeptide HL12-CP 1.
The embodiment mainly aims to obtain the positive phage specifically combined with the CD133 through screening, amplifying and purifying the positive phage, extracting phage single-stranded DNA (ssDNA) for sequencing, analyzing and comparing the obtained sequences, and finally synthesizing the antagonist polypeptide HL12-CP1 with high purity.
The method comprises the following specific steps:
1. establishing a 293T cell line permanently expressing CD 133: 293T-CD133+/+
① A well-growing, light-emitting human 293T cell was selected at 5 × 10 days before transfection5One/well, inoculating in 6-well plate, culturing until the cell fusion degree is 60% after the second day;
② the second day, with 6 hole plate culture hole as a unit, using 200 u L of opti-MEM medium dilution 3 u g plasmid, another 200 u L opti-MEM medium dilution 6 u L liposome Lipofectamine2000, after gently mixing, placed at room temperature for 5 minutes;
③ mixing the two tube dilutions gently, standing for 20 minutes at room temperature, and then adding 600 μ L of opti-MEM culture medium gently into the mixed dilutions;
rinsing the cells to be transfected with PBS slightly once, then adding the mixed diluent into the culture holes slightly, and culturing in a carbon dioxide incubator;
fifthly, after culturing for 4-6 hours, abandoning the culture medium used for transfection, and adding 3mL of complete culture medium into the hole;
sixthly, selecting a culture medium containing 1 mu g/mL puromycin (puromycin) for screening after 48 hours; and obtaining the 293T cell line stably expressing the CD133 after the cell is not dead any more.
Seventhly, extracting total RNA by using TRIzol, quantifying 2 mug of RNA for reverse transcription (a reverse transcription kit, purchased from Promega corporation), and performing qPCR by using a specific primer sequence.
The sequence of the specific primer is Hu-CD133 primer sequence:
Fw 5’-GAGCTAAGGGAAGGGCGG-3’SEQ ID No:2
Rv 5’-ATAAACAGCAGCCCCAGGAC-3’SEQ ID No:3
⑧ comparison with transfected pSM2c-Hu-scramble RNA, the expression level of CD133 was high and was designated 293T-CD133+/+And the method can be used for screening positive phage.
2. Performing panning, amplification, purification, sequencing and synthesis of the CD133 antagonist polypeptide
① ER2738 host bacteria liquid preparation, aseptic technique operation, taking 200 mul LB-Tet liquid culture medium in 1.5mL sterilized centrifuge tube, taking 0.2 mul bacteria liquid from the glycerol frozen stock of E.coli ER2738, mixing well, sucking all the liquid and coating on LB-Tet plate, marking the plate, placing at room temperature for 3min, placing in 37 ℃ constant temperature incubator for overnight culture, observing the next day, sealing with sealing film after growing clone, storing at 4 ℃ in dark place, picking single colony by aseptic technique with sterilizing gun head, placing in 10mL sterilized centrifuge tube with 3mL LB-Tet liquid culture medium in advance, marking, placing in 37 ℃ constant temperature shaker, shaking culture at 300rpm/min overnight, storing at the next day, bacterial amplification liquid at 4 ℃ for later use, taking 10mL sterilized centrifuge tube, adding 3mL LB-Tet liquid culture medium in aseptic operation, inoculating 30 mul cultured bacteria, shaking culture at 37 ℃ for 2-3 h at constant temperature shaker/min, observing the bacteria in visual inspection (OD) overnight growth period600～0.5)。
② panning of CD133 antagonistic peptide high expressing CD133 cells were selected as 105Culture dishInoculating to 60 × 15mm precoated with polylysine2In a culture dish, when the cells are cultured to 80-90% in a conventional way, 1 mu L of eluent is firstly taken for each round of elutriation (meanwhile, a cell line which does not express CD133 is used as a blank control), the rest eluent is added into 20mL of LB culture solution for amplification, then purification and the titer after amplification are measured, an amplified product is stored at 4 ℃ for a short time, the same magnitude is taken for the next round of elutriation, and the rest amplified product is stored at-20 ℃ by using 50% of glycerol.
③ measurement of phage titer 4 sterilized 10mL centrifuge tubes were taken, 1 sterilized centrifuge tube was prepared for each phage dilution, Top agar (agar Top) was melted in a microwave oven, 3mL Top agar was added to each tube, a water bath was run at 45 ℃ and 1 LB/IPTG/Xgal plate was prepared for each phage dilution, a 37 ℃ incubator was preheated and OD was used600Coli ER2738 E.coli 0.5 was aliquoted at phage dilution 200. mu.L/tube and stored at 4 ℃ for future use. Taking 4 sterilized 1.5mL centrifuge tubes, respectively containing 100 μ L, 90 μ L LB-Tet culture medium, sucking 1 μ L of bacteriophage to be tested into 100 μ L LB-Tet culture medium, diluting according to 10 times gradient, respectively marking as 10-1、10-2、10-3、10-4And each dilution is mixed evenly by gentle oscillation and then is centrifuged instantly. Mix 10 μ L of each dilution of phage to be titrated with 200 μ L of e.coli ER2738, mix by gentle shaking, centrifuge instantaneously, incubate for 5min at room temperature. Quickly adding the mixed bacterial liquid into top agar, quickly shaking and uniformly mixing, immediately pouring into a preheated LB/IPTG/Xgal plate, uniformly flattening, cooling at room temperature for 5min, and inversely culturing the plate in a constant-temperature incubator at 37 ℃ overnight.
Amplification and purification of eluted phage: taking a 250mL conical flask, adding the overnight cultured ER2738 host bacterial liquid into 20mL LB liquid culture medium according to the proportion of 1:100, and carrying out vigorous shaking culture at 37 ℃ and 250rpm for 2 h; then adding the phage liquid to be amplified into an erlenmeyer flask, and carrying out vigorous shaking culture at 37 ℃ and 250rpm for 4.5 h; the culture was transferred to a 50mL centrifuge tube and centrifuged at 10,000rpm at 4 ℃ for 10 min. Transferring the supernatant into another clean centrifugal tube, and centrifuging again at 10,000rpm at 4 ℃ for 10 min; transferring 80% of the supernatant into another clean centrifuge tube, adding 1/4 volume of PEG/NaCl, reversing, mixing uniformly, and precipitating at 4 ℃ overnight; the next day, the pellet was centrifuged at 12000rpm for 20min at 4 ℃. Carefully sucking the supernatant with a clean gun head, centrifuging at 4 deg.C and 12,000rpm for 1min, and removing the residual supernatant; the pellet was then resuspended in 1mL TBS and gently pipetted 100 times. Then transferring the suspension into a 2mL centrifuge tube, and centrifuging at 4 ℃ and 10000rpm for 5min to remove residual cells; adding 1/4 volume of PEG/NaCl to the supernatant, and incubating on ice for 60min for reprecipitation; taking out the centrifuge tube, centrifuging at 4 ℃ and 12000rpm for 20min, and removing the supernatant; the pellet was resuspended in 200. mu.L TBS and centrifuged at 10,000rpm for 1min at 4 ℃. The supernatant was transferred to another centrifuge tube. Short-term storage at 4 deg.C, or long-term storage at-20 deg.C with 50% glycerol. The amplification of the monoclonal phage comprises the steps of adding overnight cultured ER2738 host bacterial liquid into 2mL of LB liquid culture medium according to the proportion of 1:100, and carrying out vigorous shaking culture at 37 ℃ and 250rpm for 2 h; selecting a plate with less than 100 plaques from the fourth round of titer plates by using a sterilizing toothpick, picking well-separated blue plaques, adding the blue plaques into a culture tube, and carrying out violent shake culture at 37 ℃ and 250r/min for 4.5 h; the culture was then transferred to a fresh centrifuge tube and centrifuged at 10,000rpm for 30sec at 4 ℃. Transferring the supernatant into a fresh tube, and centrifuging once again; 80% of the supernatant was transferred to fresh centrifuge tubes and stored at 4 ℃ or stored with 50% glycerol for a long period at-20 ℃.
Identifying M13 bacteriophage ssDNA by agarose gel electrophoresis: horizontally placing a gel forming mold, placing the selected comb, and reserving a space of 1mm between the bottom of the comb and the mold; weighing 1g of agarose for DNA electrophoresis, putting the agarose into a 250mL Erlenmeyer flask, adding 100mL of 1 XTAE buffer solution, uniformly mixing, putting the flask into a microwave oven, heating and boiling until the agarose is completely dissolved; and (3) closing the induction cooker, taking out the triangular flask, cooling the triangular flask to room temperature (which can be tolerated by holding the flask by hand), adding 5 mu L of ethidium bromide, and pouring the gel solution into a rubber plate paving plate after uniformly mixing. The rubber plate used in the experiment needs about 100mL of rubber solution; after the gel is completely solidified at room temperature and takes about 30 minutes, pulling out the comb teeth, and putting the rubber plate into an electrophoresis tank; adding 1 XTAE buffer solution into the electrophoresis tank, preferably 2mm higher than the surface of the gel; diluting the sample with a Loading buffer, adding the diluted sample into a gel plate, and paying attention to that a suction head of a sample injector is just placed in a gel point sample hole, the gel cannot be punctured, and the sample is prevented from overflowing out of the hole; switching on a power supply, adjusting the voltage to 50V, performing electrophoresis for 90min, taking out the gel plate, and observing the result under an ultraviolet lamp.
Sequencing and sequence analysis of ssDNA: the extracted M13 phage ssDNA was sent to Shanghai Yingji Biotechnology Ltd for DNA sequencing. Sequencing was followed by sequence analysis using Bioedit software. According to the analysis result, the sequence of the sample is Gln-Gln-Met-His-Glu-Trp-Tyr-Phe-Gln-Ser-Leu-Pro, expressed as HL12-CP1, and finally the short peptide is obtained from Federation peptide Biotech Co.
The hydrophobic profile analysis of FIG. 1 demonstrates the potential for effective binding of HL12-CP1 polypeptide to CD 133.
Example 2 detection of binding of phage monoclonal to CD133 by ELISA
First, a single clone of the phage HL12-CP1 was picked up, inoculated in LB medium containing ER2738, and shake-cultured at 37 ℃ and 230rpm for 7 hours. Centrifuging at 5000rpm for 15min at normal temperature, collecting supernatant, and storing at 4 deg.C. 293T wild type cells, 293TCD133+/+Cells, HCT-116 cells and HT-29 cells were 5 × 10 per well3One was inoculated in a 96-well plate and cultured for 24 hours. The next day, the cell culture medium was discarded and blocked for 2 hours by adding blocking solution (DMEM + 5% BSA) to each well. After discarding the blocking solution, 100. mu.L of phage dilution (1:100) was added to each well for 2 hours. Then PBST (PBS + 0.1% Tween-20) washing 3 times, each time for 5min to remove the unbound phage. mu.L of peroxidase-linked anti-M13 phage antibody (purchased from GE) after dilution (1:5000) was added to each well and allowed to act for 1 hour at room temperature. PBST (PBS + 0.1% Tween-20) was washed 3 times for 5min each to remove unbound antibody. Add 50. mu.L of LTMB substrate (Sigma) to each well, shield from light for 30 min at room temperature, and 50. mu.L of concentrated H to each well2SO4The reaction was stopped and read at 450nm using a microplate reader. As a result, it was found that the HL12-CP1 phage was higher in CD 133-highly expressed 293T CD133 than 293T wild-type cells not expressing CD133+/+The cells, HCT-116 cells and HT-29 cells have higher binding capacity, and the difference is significant (***P is less than 0.001), the results are shown inFig. 2.
Example 3 HL12-CP1 can significantly inhibit the proliferation of colorectal cancer cell HCT-116
① colorectal cancer cell HCT-116 was treated with 5 × 103Inoculating each well into a 96-well cell culture plate, culturing for 24h with the culture medium volume of 200 mu L per well, and then starving overnight;
adding HL12-CP1 polypeptide with different concentration gradients (100 mu M, 10 mu M, 1 mu M, 0.1 mu M, 0.01 mu M and 0.001 mu M) to culture for 24 hours, 48 hours and 72 hours respectively;
③ adding 20 mu L of MTT working solution into each hole, and continuously putting into a carbon dioxide incubator to culture for 4 hours;
and fourthly, abandoning the supernatant in the culture plate, adding 150 mu L DMSO (dimethyl sulfoxide), shaking for 10 minutes, selecting 490nm wavelength on a microplate reader for detection, and drawing a growth curve of the cells.
In the previous work of the inventor laboratory, the colorectal cancer cells HCT-116 are detected to highly express CD133 through a q-PCR test. FIG. 3 shows that different concentrations of HL12-CP1 short peptide can obviously inhibit the proliferation of the colorectal cancer cell HCT-116 cell, and the effect of the short peptide on inhibiting the proliferation of the colorectal cancer cell HCT-116 cell is more obvious along with the increase of the action time.
Example 4 HL12-CP1 can promote apoptosis of colorectal cancer cell HCT-116
① colorectal cancer cell HCT-116 was treated with 5 × 105Inoculating each cell/well in 6-well cell culture plates, culturing for 24h with the volume of culture medium per well being 1mL, and then starving overnight;
adding HL12-CP1 polypeptide with different concentration gradients (1 mu M, 0.1 mu M and 0.01 mu M) to culture for 24 hours, 48 hours and 72 hours respectively;
thirdly, collecting the supernatant into a centrifuge tube, and then carefully digesting and collecting the cell culture solution into the centrifuge tube by using pancreatin without EDTA. Centrifuging about 500g for 5 minutes to precipitate cells;
fourthly, washing the cells twice by using precooled PBS, and centrifuging about 500g for 5 minutes to collect the cells;
adding 100 μ L of precooled 1 × annexin V Binding Buffer, and resuspending the cells;
sixthly, adding 5 mu L annexin V-FITC and 5 mu L PI, mixing evenly, and reacting for 15 minutes in a dark place at room temperature;
seventhly, adding 400 mu L of precooled 1 × annexin V Binding Buffer, mixing the mixture evenly, placing the sample on ice in a dark place, and detecting the sample by a flow cytometer within 1 hour. And analyzing the detection result.
FIG. 4 shows that HL12-CP1 short peptide can obviously promote the apoptosis of HCT-116 of colorectal cancer cells along with the increase of action concentration through flow cytometry analysis. Compared with the control group, the compound has significant difference,**P<0.01。
SEQUENCE LISTING
<110> Shenzhen International institute for graduate of Qinghua university
<120> CD133 antagonistic polypeptide, its derivative and application
<130>CP120010384C
<160>3
<170>PatentIn version 3.3
<210>1
<211>12
<212>PRT
<213>HL12-CP1
<400>1
Gln Gln Met His Glu Trp Tyr Phe Gln Ser Leu Pro
1 5 10
<210>2
<211>18
<212>DNA
<213> Hu-CD133 primer sequences
<400>2
gagctaaggg aagggcgg 18
<210>3
<211>20
<212>DNA
<213> Hu-CD133 primer sequences
<400>3
Claims (10)
1. A CD133 antagonist polypeptide, which polypeptide comprises: the amino acid residue sequence of the CD133 antagonistic polypeptide is shown as SEQ ID No.1,
Gln-Gln-Met-His-Glu-Trp-Tyr-Phe-Gln-Ser-Leu-Pro SEQ ID No：1。
2. a derivative of the CD133 antagonist polypeptide of claim 1, wherein:
the derivative of the CD133 antagonist polypeptide is a product obtained by performing conventional modification on an amino acid side chain group of the CD133 antagonist polypeptide of claim 1, an amino terminus or a carboxyl terminus of a CD133 antagonist polypeptide fragment of claim 1, or a product obtained by attaching a tag for polypeptide or protein detection or purification to the CD133 antagonist polypeptide of claim 1;
the conventional modification is amination, amidation, hydroxylation, carboxylation, carbonylation, alkylation, acetylation, phosphorylation, esterification, glycosylation, cyclization, biotinylation, fluorescent group modification, polyethylene glycol (PEG) modification or immobilization modification;
the label is His6GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityXact.
3. A polynucleotide encoding the CD133 antagonist polypeptide of claim 1 or the derivative of claim 2.
4. A vector comprising the polynucleotide of claim 3.
5. A host cell transfected with the vector of claim 4.
6. A medicament comprising a CD133 antagonist polypeptide of claim 1 or a derivative of claim 2;
preferably, the medicament contains one or more pharmaceutically acceptable carriers;
more preferably, the pharmaceutically acceptable carrier is a diluent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, adsorption carrier, surfactant or lubricant.
7. A detection reagent comprising the CD133 antagonist polypeptide of claim 1 or the derivative of claim 2.
8. An antibody to a CD133 antagonist polypeptide or a derivative of a CD133 antagonist polypeptide, wherein the CD133 antagonist polypeptide is the CD133 antagonist polypeptide of claim 1, and wherein the derivative of the CD133 antagonist polypeptide is the derivative of claim 2.
9. Use of the CD133 antagonist polypeptide of claim 1 or a derivative of the CD133 antagonist polypeptide of claim 2 for the preparation of a medicament for inhibiting proliferation or promoting apoptosis of tumor cells that highly express CD 133;
preferably, the tumor cells highly expressing CD133 are selected from the group consisting of rectal cancer cells, colon cancer cells, bile duct cancer cells, glioma cells, endometrial cancer cells, lung cancer cells, gastric adenocarcinoma cells.
10. Use of the CD133 antagonist polypeptide of claim 1 or a derivative of the CD133 antagonist polypeptide of claim 2 for the preparation of a medicament for the treatment of a tumor disease that is highly expressing CD 133;
preferably, the tumor diseases with high expression of CD133 are selected from rectal cancer, colon cancer, bile duct cancer, glioma, endometrial cancer, lung cancer and gastric adenocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010553810.5A CN111560053B (en) | 2020-06-17 | 2020-06-17 | CD133 antagonistic polypeptide, derivative and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010553810.5A CN111560053B (en) | 2020-06-17 | 2020-06-17 | CD133 antagonistic polypeptide, derivative and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111560053A true CN111560053A (en) | 2020-08-21 |
| CN111560053B CN111560053B (en) | 2022-05-27 |
Family
ID=72068769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010553810.5A Active CN111560053B (en) | 2020-06-17 | 2020-06-17 | CD133 antagonistic polypeptide, derivative and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111560053B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112920258A (en) * | 2021-03-05 | 2021-06-08 | 清华大学深圳国际研究生院 | CD44 antagonistic polypeptide and derivative and application thereof |
| CN113087772A (en) * | 2021-04-27 | 2021-07-09 | 清华大学深圳国际研究生院 | RHAMM antagonistic polypeptide, derivative and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2251604A1 (en) * | 1996-04-26 | 1997-11-06 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen and methods for its use |
| CN101391115A (en) * | 2008-11-12 | 2009-03-25 | 乐普（北京）医疗器械股份有限公司 | Preparation method of biological activity protein or polypeptides coating biology bracket |
| CN101601610A (en) * | 2008-07-15 | 2009-12-16 | 乐普（北京）医疗器械股份有限公司 | A kind of novel biological antibody medical device and preparation method thereof |
| WO2011094430A2 (en) * | 2010-01-27 | 2011-08-04 | Children's Medical Center Corporation | Pro-angiogenic fragments of prominin-1 and uses thereof |
| CN103068850A (en) * | 2010-05-26 | 2013-04-24 | 明尼苏达大学评议会 | Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| AU2015202047A1 (en) * | 2008-07-28 | 2015-05-21 | Children's Medical Center Corporation | Prominin-1 peptide fragments and uses thereof |
| CN106220712A (en) * | 2016-07-19 | 2016-12-14 | 清华大学深圳研究生院 | Polypeptide, nucleic acid and application thereof |
| EP3632460A1 (en) * | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| US20200230199A1 (en) * | 2017-06-01 | 2020-07-23 | Children's Medical Center Corporation | Prominin-1 peptide for treating lung injury |
| CN113307849A (en) * | 2020-12-15 | 2021-08-27 | 北京理工大学 | Stapler peptide of targeting tumor stem cell marker CD133 and application thereof |
-
2020
- 2020-06-17 CN CN202010553810.5A patent/CN111560053B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2251604A1 (en) * | 1996-04-26 | 1997-11-06 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen and methods for its use |
| CN101601610A (en) * | 2008-07-15 | 2009-12-16 | 乐普（北京）医疗器械股份有限公司 | A kind of novel biological antibody medical device and preparation method thereof |
| AU2015202047A1 (en) * | 2008-07-28 | 2015-05-21 | Children's Medical Center Corporation | Prominin-1 peptide fragments and uses thereof |
| CN101391115A (en) * | 2008-11-12 | 2009-03-25 | 乐普（北京）医疗器械股份有限公司 | Preparation method of biological activity protein or polypeptides coating biology bracket |
| WO2011094430A2 (en) * | 2010-01-27 | 2011-08-04 | Children's Medical Center Corporation | Pro-angiogenic fragments of prominin-1 and uses thereof |
| CN103068850A (en) * | 2010-05-26 | 2013-04-24 | 明尼苏达大学评议会 | Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| CN106220712A (en) * | 2016-07-19 | 2016-12-14 | 清华大学深圳研究生院 | Polypeptide, nucleic acid and application thereof |
| US20200230199A1 (en) * | 2017-06-01 | 2020-07-23 | Children's Medical Center Corporation | Prominin-1 peptide for treating lung injury |
| EP3632460A1 (en) * | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| CN113307849A (en) * | 2020-12-15 | 2021-08-27 | 北京理工大学 | Stapler peptide of targeting tumor stem cell marker CD133 and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| JINMIN SUN等: "A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro", 《CLINICAL & EXPERIMENTAL METASTASIS》 * |
| 李学农: "CD133+造血祖细胞对大肠癌细胞生物学特性的影响与探讨", 《中国优秀硕士学位论文全文数据库（电子期刊）》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112920258A (en) * | 2021-03-05 | 2021-06-08 | 清华大学深圳国际研究生院 | CD44 antagonistic polypeptide and derivative and application thereof |
| CN113087772A (en) * | 2021-04-27 | 2021-07-09 | 清华大学深圳国际研究生院 | RHAMM antagonistic polypeptide, derivative and application thereof |
| CN113087772B (en) * | 2021-04-27 | 2022-04-22 | 清华大学深圳国际研究生院 | RHAMM antagonistic polypeptide, derivative and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111560053B (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111560053B (en) | CD133 antagonistic polypeptide, derivative and application thereof | |
| CN111647046B (en) | CD133 antagonistic polypeptide, derivative and application thereof | |
| CN111548390B (en) | CD133 antagonistic polypeptide, derivative and application thereof | |
| CN110330551B (en) | Pancreatic cancer specific binding peptide and preparation method and application thereof | |
| CN110317243B (en) | RAGE (receptor for activating receptor) antagonistic polypeptide and application thereof | |
| CN111647047B (en) | CD133 antagonistic polypeptide, derivative and application thereof | |
| CN111647045B (en) | CD133 antagonistic polypeptide, derivative and application thereof | |
| CN113480603B (en) | Specific short peptide targeting glioma cells, coding gene and application thereof | |
| CN111254130B (en) | Method for inhibiting tumor growth by DDX24 helicase point mutation and application thereof | |
| CN112920258B (en) | CD44 antagonistic polypeptide, derivative and application thereof | |
| CN109942670B (en) | GPR1 antagonistic polypeptide, and derivative and application thereof | |
| CN109942673B (en) | GPR1 antagonistic polypeptide, and derivative and application thereof | |
| CN113214360B (en) | RHAMM antagonistic polypeptide, derivative and application thereof | |
| CN113087772B (en) | RHAMM antagonistic polypeptide, derivative and application thereof | |
| WO2021083248A1 (en) | Anti-tspan8 monoclonal antibody and use thereof | |
| CN109942683A (en) | A kind of CMKLR1 antagonism polypeptide and its derivative and application | |
| CN109942676B (en) | CMKLR1 antagonistic polypeptide and derivative and application thereof | |
| CN113185579B (en) | FMOD antagonistic polypeptide and derivative and application thereof | |
| CN109942682B (en) | CMKLR1 antagonistic polypeptide and derivative and application thereof | |
| CN113501863B (en) | Mucin13 antagonistic polypeptide, derivative and application thereof | |
| CN109942684B (en) | CMKLR1 antagonistic polypeptide and derivative and application thereof | |
| CN113717252B (en) | CD44 antagonistic polypeptide and derivative and application thereof | |
| CN106701904B (en) | Application of ACSL4 gene and expression product in diagnosis and treatment of gastric cancer | |
| CN110317244B (en) | RAGE (receptor for activating receptor) antagonistic polypeptide and application thereof | |
| CN113461783B (en) | Podophyllin antagonistic polypeptide and derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |